Published in Cytotherapy on January 01, 2004
Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature (1985) 9.62
"Infectious" transplantation tolerance. Science (1993) 4.98
Reshaping human antibodies for therapy. Nature (1988) 4.82
Antibody-coated bacteria in the urine and the site of urinary-tract infection. N Engl J Med (1974) 4.77
CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med (1989) 4.19
Impaired resistance to Mycobacterium tuberculosis infection after selective in vivo depletion of L3T4+ and Lyt-2+ T cells. Infect Immun (1987) 3.87
Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med (1987) 3.82
Different roles for L3T4+ and Lyt 2+ T cell subsets in the control of an acute herpes simplex virus infection of the skin and nervous system. J Gen Virol (1987) 3.16
Functional analysis of T lymphocyte subsets in antiviral host defense. J Immunol (1987) 3.11
Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology (1990) 2.77
Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia (2010) 2.65
Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet (1988) 2.51
Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol (1999) 2.28
Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet (1998) 2.26
Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance. Nature (1986) 2.25
Colonoscopic study of 50 patients with colonic tuberculosis. Gut (1992) 2.06
IL-10 gene expression is controlled by the transcription factors Sp1 and Sp3. J Immunol (2000) 2.04
Association of cathepsin B gene polymorphisms with tropical calcific pancreatitis. Gut (2006) 1.97
Letter: T cell-dependent mediator in the immune response. Nature (1973) 1.94
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood (2000) 1.93
Induction of classical transplantation tolerance in the adult. J Exp Med (1989) 1.91
The effect on the growth of BP8 ascites tumour in C3H-C57 or C3H mice of "lymphocyte preparations" from C57 mice injected with BP8 cells and Freund's adjuvant. Br J Cancer (1967) 1.88
Limiting dilution analysis of helper T-cell function. Immunology (1975) 1.82
Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood (1983) 1.80
Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest (1991) 1.79
Induction of tolerance in peripheral T cells with monoclonal antibodies. Eur J Immunol (1990) 1.79
Monocytic origin of foam cells in human atherosclerotic plaques. Atherosclerosis (1984) 1.78
The CAMPATH-1 antigen (CDw52). Tissue Antigens (1990) 1.78
Mechanisms of peripheral tolerance and suppression induced by monoclonal antibodies to CD4 and CD8. Immunol Rev (1996) 1.77
The rectus sheath block in paediatric anaesthesia: new indications for an old technique? Paediatr Anaesth (1996) 1.76
T cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host disease. Bone Marrow Transplant (1994) 1.76
Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet (1992) 1.72
Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet (1999) 1.69
Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation (1999) 1.67
Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia. Arthritis Rheum (2001) 1.67
Self-assembly and catalytic activity of the pyruvate dehydrogenase multienzyme complex of Escherichia coli. Nature (1977) 1.67
Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies. QJM (1996) 1.66
T cell-dependent mediator in the immune response. II. Physical and biological properties. Immunology (1974) 1.65
The influence of the major histocompatibility complex on the function of T-helper cells in antibody formation. Immunol Rev (1978) 1.64
Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J Exp Med (1988) 1.63
Posttranscriptional regulation of IL-10 gene expression through sequences in the 3'-untranslated region. J Immunol (2000) 1.60
Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet (1994) 1.59
In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium. Science (1995) 1.56
Cutting edge: anti-CD154 therapeutic antibodies induce infectious transplantation tolerance. J Immunol (2000) 1.55
Induction of tolerance by monoclonal antibody therapy. Nature (1986) 1.53
Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2and c-Myc expression. Oncogene (2001) 1.53
Allogeneic bone marrow transplantation for infants with acute leukemia or myelodysplastic syndrome. Bone Marrow Transplant (2001) 1.52
Cooperation across the histocompatibility barrier. Nature (1975) 1.51
CD40 ligand blockade induces CD4+ T cell tolerance and linked suppression. J Immunol (1999) 1.50
Fitness within sport. Br J Sports Med (1977) 1.50
Conditions determining the generation and expression of T helper cells. Immunol Rev (1977) 1.49
Skin allograft rejection by L3/T4+ and Lyt-2+ T cell subsets. Transplantation (1986) 1.49
Antigen-non-specific T-cell factor in B-cell activation. Origin, biological properties and failure to show a relationship to H-2. Immunology (1976) 1.49
Molecular weight and symmetry of the pyruvate dehydrogenase multienzyme complex of Escherichia coli. J Mol Biol (1979) 1.48
Self tolerance is H-2-restricted. Nature (1984) 1.47
Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J (1993) 1.46
T cell suppression in transplantation tolerance through linked recognition. J Immunol (1996) 1.45
The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol (1993) 1.44
Regulation of IL-18 (IFN-gamma-inducing factor) gene expression. J Immunol (1997) 1.44
Antifungal effects of the nonlinear pharmacokinetics of cilofungin, a 1,3-beta-glucan synthetase inhibitor, during continuous and intermittent intravenous infusions in treatment of experimental disseminated candidiasis. Antimicrob Agents Chemother (1991) 1.41
Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain (1996) 1.40
Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet (1993) 1.40
The role of CD4+ T-cell subsets in determining transplantation rejection or tolerance. Immunol Rev (2001) 1.40
Infectious tolerance. Curr Opin Immunol (1998) 1.39
T cell-dependent mediator in the immune response. III. The role of non-specific factor (NSF) in the in vitro immune response. Immunology (1975) 1.39
Amplification of natural regulatory immune mechanisms for transplantation tolerance. Transplantation (1996) 1.39
Use of Ceprate CD34-positive selection system for depletion of T cells in allogeneic transplantation. Bone Marrow Transplant (1997) 1.39
The induction of skin graft tolerance in major histocompatibility complex-mismatched or primed recipients: primed T cells can be tolerized in the periphery with anti-CD4 and anti-CD8 antibodies. Eur J Immunol (1990) 1.39
Regulation of CD40 function by its isoforms generated through alternative splicing. Proc Natl Acad Sci U S A (2001) 1.38
A rapid solid-phase enzyme-linked binding assay for screening monoclonal antibodies to cell surface antigens. J Immunol Methods (1981) 1.38
Therapeutic potential of rat monoclonal antibodies: isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes. J Immunol (1985) 1.37
Resistance of bacterial biofilms to disinfectants: a review. Biofouling (2011) 1.34
Amidination of pyruvate dehydrogenase complex of Escherichia coli under denaturing conditions. Biochem J (1979) 1.34
Identification of macrophages and smooth muscle cells in human atherosclerosis using monoclonal antibodies. J Pathol (1985) 1.34
Do L3T4+ T cells act as effector cells in protection against influenza virus infection. Immunology (1987) 1.33
Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest (1996) 1.33
Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med (1986) 1.33
Monoclonal-antibody therapy in systemic vasculitis. N Engl J Med (1990) 1.32